[opensourcepharma] Open Source Pharma Items

[Matthew Todd]

Dear all,

Some recent items of interest related to open source pharma. As always,
please forward to anyone you feel might be interested.

1. Citizen science project called Bash the Bug
<https://wellcome.ac.uk/news/public-invited-help-tackle-antibiotic-resistance>
aimed at identifying new anti-TB compounds.
2. Short article on open drug development in the Yale Journal of Biology
and Medicine <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5369032/>
3. A comment in Nature on "Five ways consortia can catalyse open science
<http://www.nature.com/news/five-ways-consortia-can-catalyse-open-science-1.21706>
".
4. A new group called the Collaborative Knowledge Foundation
<https://coko.foundation/> interested in changing the way we publish.
5. 2016 G-finder report
<http://www.policycuresresearch.org/downloads/Y9%20GFINDER%20full%20report%20web.pdf>
(PDF) from Policy Cures on NTDs.
6. An interesting example
<http://www.nature.com/news/open-data-contest-unearths-scientific-gems-and-controversy-1.21572>
of how opening up clinical data may allow onlookers to publish more quickly
than the original team.
7. Crowdsourcing for Alzheimer's disease
<https://medium.com/@crowdandcloud/how-citizen-scientists-could-help-find-a-cure-for-alzheimer-s-disease-74f390d78a2>,
in the eyesonalz <http://eyesonalz.com/> project in which citizen
scientists search for blood flow patterns in the brain. Featured in the
documentary Crowd and the Cloud <http://crowdandcloud.org/about-the-series>.
8. The IFPMA roadmap to combat AMR
<http://www.ifpma.org/resource-centre/leading-pharmaceutical-companies-present-industry-roadmap-to-combat-antimicrobial-resistance/>
(Sept 2016) includes as one of the four recommendations "Explore new
opportunities for open collaborations between industry and the public
sector"
9. Article
<http://journals.plos.org/plosbiology/article?id=10.1371/journal.pbio.2001259>
on the patent-free experiment being carried out by the Montreal
Neurological Institute.
10. An op-ed call to "industrialise rare disease therapy discovery and
development <http://www.nature.com/nbt/journal/v35/n2/full/nbt.3787.html>"
in part by centralisation of common approaches and greater openness.
11. Drug Repurposing Hub
<http://www.nature.com/nm/journal/v23/n4/full/nm.4306.html>, from the Broad
Institute.
12. Crowdsourcing student organic chemistry by DNDi for leishmaniasis
<https://www.dndi.org/2017/media-centre/press-releases/universities-drug-discovery-neglected-diseases/>
.
13. A book, Good Pharma
<http://link.springer.com/book/10.1057/9781137374332>, I wasn't aware of,
published in 2015, that describes the unusual approach taken to drug
discovery by the Mario Negri Institute in Italy.
14. The WHO/Dutch Ministry of Health Forum on Fair Pricing
<http://www.fairpricingforum2017.nl/home> is happening at the moment in
Amsterdam.

And in case you'd not seen it: a paper by me and some others on this email
list sketching out a roadmap for Open Source Pharma
<http://journals.plos.org/plosmedicine/article?id=10.1371/journal.pmed.1002276>,
with a lay piece in the Guardian
<https://www.theguardian.com/commentisfree/2017/apr/19/why-open-source-pharma-is-the-path-to-both-cheaper-and-new-medicines>
.

I'll be at an interesting meeting later this month at the Beilstein
Institute <http://www.beilstein-institut.de/en/symposia/open-science> on
the Chemistry Lab of the Future, which will be sure to raise issues
relevant to how we can better carry out R&D in the earlier stages of drug
dev.

Best,

Mat




-- 
MATTHEW TODD | Associate Professor
School of Chemistry | Faculty of Science

THE UNIVERSITY OF SYDNEY
Rm 519, F11 | The University of Sydney | NSW | 2006
T +61 2 9351 2180 <+61%202%209351%202180>  | F +61 2 9351 3329
<+61%202%209351%203329>  | M +61 415 274104 <+61%20415%20274%20104>
E matthew.todd at sydney.edu.au | W http://sydney.edu.au/science/
people/matthew.todd.php
W http://opensourcemalaria.org/ | W http://opensourcetb.org/ | W
http://opensourcepharma.net/

CRICOS 00026A
This email plus any attachments to it are confidential. Any unauthorised
use is strictly prohibited. If you receive this email in error, please
delete it and any attachments.
-------------- next part --------------
An HTML attachment was scrubbed...
URL: <http://lists.okfn.org/pipermail/opensourcepharma/attachments/20170511/d5825377/attachment.html>